Spectrum of effectiveness of valproate in neuropsychiatry

References

• Pope HG Jr, McElroy SL, Keck PE Jr et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch. Gen. Psychiatry 48, 62–68 (1991).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 271, 918–924 (1994).
   PubMed Web of Science ®Google Scholar
• Bowden CL. Valproate. Bipolar Disord. 5, 189–202 (2003).
   PubMed Web of Science ®Google Scholar
• Siafaka-Kapadai A, Patiris M, Bowden C et al. Incorporation of [3H]-Valproic Acid into Lipids in GT1–7 Neurons. Biochem. Pharmacol. 56, 207–212 (1998).
   PubMedGoogle Scholar
• Horie S, Suga T. Enhancement of peroxisomal beta-oxidation in the liver of rates and mice treatment with valproic acid. Biochem. Pharmacol. 34, 1357–1362 (1985).
   PubMed Web of Science ®Google Scholar
• Post RM, Leverich GS, Altshuler LL et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord. 5, 310 (2003).
   PubMed Web of Science ®Google Scholar
• Einat H, Yuan P, Gould TD et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23, 7311–7316 (2003).
   PubMed Web of Science ®Google Scholar
• Gould TD, ChenG, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29, 32–38 (2004).
   PubMed Web of Science ®Google Scholar
• Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem. Pharmacol. 66, 179–189 (2003).
   PubMed Web of Science ®Google Scholar
• Gray NA, Zhou R, Du J et al. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. J. Clin. Psychiatry 64(S), 3–17 (2003).
   PubMedGoogle Scholar
• Brunello N, Tascedda F. Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int. J. Neuropsychopharmacol. 6, 181–189 (2003).
   Google Scholar
• Watterson JM, Watson DG, Meyer EM et al. A role for protein kinase C and its substrates in the action of valproic acid in the brain: implications for neural plasticity. Brain Res. 934, 69–80 (2002).
   Google Scholar
• Lieb K, Treffurth Y, Hamke M et al. Valproic acid inhibits substance P-induced ativiation of proten in kinase C epsilon and expression of the substance P receptor. J. Neurochem. 86, 69–76 (2003).
   PubMed Web of Science ®Google Scholar
• Tremolizzo L, Doueiri MS, Dong E et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol. Psychiatry 57, 500–509 (2005).
   PubMed Web of Science ®Google Scholar
• Veldic M, Guidotti A, Maloku E et al. In psychosis optical interneurons overexpress DNA-methyltransferase 1. Proc. Natl Acad. Sci. USA 102, 2152–2157 (2005).
   PubMed Web of Science ®Google Scholar
• Gobbi G, Janiri L. Sodium – and magnesium – valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psycopharmacology 185, 255–262 (2006).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE, Stanton SP et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J. Clin. Psychiatry 57, 142–146 (1996).
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker R, Altshuler LL et al. Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry 159, 1011–1017 (2002).
   PubMed Web of Science ®Google Scholar
• Zajecka J, Weisler R, Sachs G et al. A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry 63, 1148–1155 (2002).
   PubMed Web of Science ®Google Scholar
• Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology 150, 15–23 (2000).
   PubMed Web of Science ®Google Scholar
• Reviki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM. Divalproex sodium versus olanzapine in the treatment of bipolar disorder: health related quality of life and medical cost outcomes. J. Clin. Psychiatry (2006) (In press).
   Google Scholar
• Solomon DA, Ryan CE, Keitner GI et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J. Clin. Psychiatry 58, 95–99 (1997).
   PubMed Web of Science ®Google Scholar
• Muller-Oerlinghausen B, Retzow A, Henn FA et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J. Clin. Psychopharmacol. 20, 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxentine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 61, 1079–1088 (2004).
   Google Scholar
• Sachs G, Grossman F, Ghaemi SN et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry 159, 1146–1154 (2002).
   PubMed Web of Science ®Google Scholar
• Freeman TW, Clothier JL, Pazzaglia P et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am. J. Psychiatry 149, 108–111 (1992).
   PubMed Web of Science ®Google Scholar
• Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J. Clin. Psychiatry 61(Suppl. 9), 35–40 (2000).
   PubMed Web of Science ®Google Scholar
• Swann AC, Bowden CL, Calabrese JR et al. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr. Scand. 101, 444–451 (2000).
   PubMed Web of Science ®Google Scholar
• Goodwin F, Bowden C, Calabrese J et al. Concomitant use of lamotrigine and lithium in bipolar I disorder. Presented at the American College of Neuropsychopharmacology Annual Meeting San Juan, Puerto Rico, December (2003) (Abstract).
   Google Scholar
• Kowatch RA, Suppes T, Carmody TJ et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 39, 713–720 (2000).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Baker JD, Wozniak P et al. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placbeo in the treatment of acute mania associated with bipolar disorder. J. Clin. Psychiatry 64, 841–846 (2003).
   PubMed Web of Science ®Google Scholar
• Swann AC, Bowden CL, Calabrese JR et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 26, 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• Bowden CL. Predictors of response to divalproex and lithium. J. Clin. Psychiatry 56, 25–30 (1995).
   PubMedGoogle Scholar
• Bowden CL, Janicak PG, Orsulak P et al. Relation of serum valproate concentration to response in mania. Am. J. Psychiatry 153, 765–770 (1996).
   PubMed Web of Science ®Google Scholar
• Allen MH, Hirschfeld RM, Wozniak PJ et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am. J. Psychiatry 163, 272–275 (2006).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Swann AC et al. Divalproex sodium extended-release versus placebo in the treatment of acute mania. Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 22 (2006) (Abstract).
   Google Scholar
• Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch. Gen. Psychiatry 57, 481–489 (2000).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Collins SD, Carlson HA et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 58, 1652–1659 (2002).
   PubMed Web of Science ®Google Scholar
• Bowden CL. Acute and maintenance treatment with mood stabilizers. Int. J. Neuropsychopharmacol. 6, 269–275 (2003) (Abstract).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Collins MA, McElroy SL et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium or placebo. Neuropsychopharmacology 30, 1932–1939 (2005).
   PubMed Web of Science ®Google Scholar
• Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28, 1374–1382 (2003).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Bowden CL, Meinhold JM et al. Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy. Int. J. Psychiatry Clin. Pract. 9, 271–277 (2005).
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br. J. Psychiatry 184, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Casey DE, Daniel DG, Wassef AA et al. Effect of divalproex combined wth olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28, 182–192 (2003).
   PubMed Web of Science ®Google Scholar
• Rasgon NL, Altshuler LL, Gudeman D et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J. Clin. Psychiatry 61, 173–178 (2000).
   PubMedGoogle Scholar
• Joffe H, Cohen LS, Suppes T et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol. Psychiatry 59, 1078–1086 (2006).
   PubMed Web of Science ®Google Scholar
• Kahn D, Stevenson E, Douglas CJ. Effect of sodium valproate in three patients with organic brain syndromes. Am. J. Psychiatry 145, 1010–1011 (1988).
   Google Scholar
• Longo LP, Campbell T, Hubatch S. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry 11, 434–440 (2003).
   Google Scholar
• Porsteinsson A, Tariot PN, Jakimovich LJ et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomized placebo controlled clinical trial. Am. J. Geriatr. Psychiatry 17, 579–585 (2002).
   Google Scholar
• Porsteinsson A, Tariot PN, Jakimovich LJ et al. Valproate therapy for agitation in dementia, open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry 11, 434–440 (2003).
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J. Clin. Psychiatry 63, 442–446 (2002).
   PubMed Web of Science ®Google Scholar
• Brady KT, Myrick H, Henderson S et al. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 67, 323–330 (2002).
   PubMed Web of Science ®Google Scholar
• Salloum IM, Cornelius JR, Daley DC et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 62, 37–45 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobsen FM. Low dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J. Clin. Psychiatry 54, 229–234 (1993).
   PubMed Web of Science ®Google Scholar
• Hollander E, Tracy KA, Swann AC et al. Divalproex in the treatment of impulsive aggressive: efficacy in cluster B personality disorders. Neuropsychopharmacology 28, 1186–1197 (2003).
   PubMed Web of Science ®Google Scholar
• Hollander E, Swann AC, Coccaro EF et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am. J. Psychiatry 162, 621–624 (2005).
   PubMed Web of Science ®Google Scholar
• Donovan SJ, Stewart JW, Nunes EV et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am. J. Psychiatry 157, 818–820 (2000).
   PubMed Web of Science ®Google Scholar
• Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 51, 634–638 (2000).
   PubMed Web of Science ®Google Scholar
• Wassef AA, Dott SG, Harris A et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J. Clin. Psychopharmacol. 20, 357–361 (2000).
   PubMed Web of Science ®Google Scholar
• Tirus MR, Yang L, Saiz FS et al. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myelobastic leukemia cells. Leukemia 19, 1161–1168 (2005).
   Google Scholar